SynthesisJournal of clinical hypertension (Greenwich, Conn.)2022
Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis.
Synthesis in Journal of clinical hypertension (Greenwich, Conn.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: A systematic review and network meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2022Pooled it
- Pharmacokinetic Variability of Direct Oral Anticoagulants and Calcium Channel Blockers: A Comparative Analysis of Exposure Data from Clinical Studies.Pharmaceutics · 2026Article
- Assessment of Cardiologists' Knowledge, Attitudes, and Practices on Calcium Channel Blocker-Induced Gingival Overgrowth.Oral health & preventive dentistry · 2026Article
- Pitfalls in the pharmacotherapy of hypertension.Clinical medicine (London, England) · 2026Review
- Incidence and risk factors of calcium channel blocker-related edema in hypertensive patients: A Multicenter retrospective cohort study.PloS one · 2026Article
- Single-Cell Transcriptomics and Lineage Tracing Unveil Parallels in Lymphatic Muscle and Venous Smooth Muscle Development, Identity, and Function.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Biginelli dihydropyrimidines and their acetylated derivatives as L-/T-type calcium channel blockers: Synthesis, enantioseparation, and molecular modeling studies.Archiv der Pharmazie · 2025Article
- Efficacy and Safety of Dihydropyridine Calcium Channel Blockers for Primary Hypertension: A Bayesian Network Meta-analysis.Current hypertension reviews · 2025Article
- The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations.Current issues in molecular biology · 2024Review
- Tolerability of Antihypertensive Medications: The Influence of Age.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024Article
- Etiology of Drug-Induced Edema: A Review of Dihydropyridine, Thiazolidinedione, and Other Medications Causing Edema.Cureus · 2024Review
- Efficacy of atorvastatin calcium on clinical manifestations and serum inflammatory markers in elderly patients with hypertension.American journal of translational research · 2024Article
- The Dysfunction of CaInternational journal of molecular sciences · 2023Review
- Article
- Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Pyrimidine Derivatives as Potential Calcium Channel Blockers.Molecules (Basel, Switzerland) · 2023Article
- Improper administration: Silent culprit of drug therapy problems.Canadian family physician Medecin de famille canadien · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dihydropyridine calcium channel blockers (DHPCCBs) are widely used to treat hypertension and chronic coronary artery disease. One common adverse effect of DHPCCBs is peripheral edema, particularly of the lower limbs. The side effect could lead to dose reduction or discontinuation of the medication. The combination of DHPCCBs and renin-angiotensin system blockers has shown to reduce the risk of DHPCCBs-associated peripheral edema compared with DHPCCBs monotherapy. We performed the current systematic review and network meta-analysis of randomized controlled trials (RCTs) to estimate the rate of peripheral edema with DHPCCBs as a class and with individual DHPCCBs and the ranking of the reduction of peripheral edema. The effects of renin-angiotensin system blockers on DHPCCBs network meta-analysis were created to analyze the ranking of the reduction of peripheral edema. A total of 3312 publications were identified and 71 studies with 56,283 patients were included. Nifedipine ranked highest in inducing peripheral edema (SUCRA 81.8%) and lacidipine (SUCRA 12.8%) ranked the least. All DHPCCBs except lacidipine resulted in higher relative risk (RR) of peripheral edema compared with placebo. Nifedipine plus angiotensin receptor blocker (SUCRA: 92.3%) did not mitigate peripheral edema and amlodipine plus angiotensin-converting enzyme inhibitors (SUCRA: 16%) reduced peripheral edema the most. Nifedipine ranked the highest and lacidipine ranked the lowest amongst DHPCCBs for developing peripheral edema when used for cardiovascular indications. The second or higher generation of DHPCCBs combination with ACEIs or ARBs or diuretics lowered the chance of peripheral edema development compared to single DHPCCB treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.